Intellia Therapeutics Awaits FDA Review for Lonvo-z, Potentially First In Vivo CRISPR Therapy
Trendline

Intellia Therapeutics Awaits FDA Review for Lonvo-z, Potentially First In Vivo CRISPR Therapy

What's Happening? Intellia Therapeutics, a biopharmaceutical company specializing in CRISPR gene editing, is moving towards a potential first approval for its lead program, lonvo-z, which targets hereditary angioedema. The company has submitted a Biologics License Application (BLA) for lonvo-z, curr
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.